Evidence map›Paper›PMID 28835697›Full record

ArticleScientific reports2017

Activation of PERK-Nrf2 oncogenic signaling promotes Mdm2-mediated Rb degradation in persistently infected HCV culture.

Yucel Aydin, Milad Chedid, Srinivas Chava, Donkita Danielle Williams, Shuanghu Liu, Curt H Hagedorn, Suchitra Sumitran-Holgersson, Krzysztof Reiss, Krzysztof Moroz, Hua Lu and 2 more

RetractedOpen access · goldAbstract readRetracted Publication
In one paragraph

Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 28 citations in OpenAlex.

  1. Article
  2. Experimental and therapeutic medicine · 2021
    Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. The Potential Role of Nrf2 Signaling in Leishmania Infection Outcomes.Frontiers in cellular and infection microbiology · 2019
    Review
  15. Article
  16. Review
  17. Article
  18. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 2 countries.

Yucel AydinDepartment of Medicine, Division of Gastroenterology and Hepatology, New Orleans, Louisiana, USA.
Milad ChedidDepartment of Pathology and Laboratory Medicine, New Orleans, Louisiana, USA.
Srinivas ChavaDepartment of Pathology and Laboratory Medicine, New Orleans, Louisiana, USA.
Donkita Danielle WilliamsDepartment of Pathology and Laboratory Medicine, New Orleans, Louisiana, USA.
Shuanghu LiuDepartment of Medicinal Chemistry, College of Pharmacy, University of Utah, Salt Lake City, UT, USA.
Curt H HagedornDepartment of Medicine and Genetics, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
Suchitra Sumitran-HolgerssonLaboratory of Transplantation Surgery and Regenerative Medicine, University of Gothenburg, Gothenburg, Sweden.
Krzysztof ReissSchool of Medicine, LSU Health Sciences Center, New Orleans, Louisiana, USA.
Krzysztof MorozDepartment of Pathology and Laboratory Medicine, New Orleans, Louisiana, USA.
Hua LuDepartment of Biochemistry, Tulane University Health Sciences Center, New Orleans, Louisiana, USA.
Luis A BalartDepartment of Medicine, Division of Gastroenterology and Hepatology, New Orleans, Louisiana, USA.
Srikanta DashDepartment of Pathology and Laboratory Medicine, New Orleans, Louisiana, USA. sdash@tulane.edu.
University of New Orleans · USLouisiana State University Health Sciences Center New Orleans · USTulane University · USUniversity of Arkansas for Medical Sciences · USUniversity of Gothenburg · SEUniversity of Utah · US

Funding

The Role of Ribosomal Proteins in the P53-MDM2 PathwayR01CA095441 · NCI · TULANE UNIVERSITY OF LOUISIANA · PI LU, HUA · 2002 to 2021
$5.1M
Role of the AMPK-MDMX-p53 pathway in cancerR01CA127724 · NCI · TULANE UNIVERSITY OF LOUISIANA · PI LU, HUA · 2007 to 2019
$3.0M
Hepatitis C Virus and Hepatocellular CarcinomaR01CA089121 · NCI · TULANE UNIVERSITY OF LOUISIANA · PI DASH, SRIKANTA · 2001 to 2016
$2.7M
IL-28B genotype and HCV treatment clearanceR01AI103106 · NIAID · TULANE UNIVERSITY OF LOUISIANA · PI DASH, SRIKANTA · 2013 to 2016
$1.5M
NCI NIH HHS R01 CA089121NCI NIH HHS R01 CA095441NCI NIH HHS R01 CA127724NIAID NIH HHS R01 AI103106
6 · The paper itself

Abstract

The mechanism of how chronic hepatitis C virus (HCV) infection leads to such a high rate of hepatocellular carcinoma (HCC) is unknown. We found that the PERK axis of endoplasmic reticulum (ER) stress elicited prominent nuclear translocation of Nrf2 in 100% of HCV infected hepatocytes. The sustained nuclear translocation of Nrf2 in chronically infected culture induces Mdm2-mediated retinoblastoma protein (Rb) degradation. Silencing PERK and Nrf2 restored Mdm2-mediated Rb degradation, suggesting that sustained activation of PERK/Nrf2 axis creates oncogenic stress in chronically infected HCV culture model. The activation of Nrf2 and its nuclear translocation were prevented by ER-stress and PERK inhibitors, suggesting that PERK axis is involved in the sustained activation of Nrf2 signaling during chronic HCV infection. Furthermore, we show that HCV clearance induced by interferon-α based antiviral normalized the ER-stress response and prevented nuclear translocation of Nrf2, whereas HCV clearance by DAAs combination does neither. In conclusion, we report here a novel mechanism for how sustained activation of PERK axis of ER-stress during chronic HCV infection activates oncogenic Nrf2 signaling that promotes hepatocyte survival and oncogenesis by inducing Mdm2-mediated Rb degradation.

Indexed as

Signal TransductionActive Transport, Cell NucleusCell LineCells, CulturedeIF-2 KinaseEndoplasmic Reticulum StressGene SilencingGenomic InstabilityHepatitis C, ChronicHepatocytesHumansImmunohistochemistryNF-E2-Related Factor 2ProteolysisProto-Oncogene Proteins c-mdm2Reactive Oxygen SpecieseIF-2 KinaseNF-E2-Related Factor 2Proto-Oncogene Proteins c-mdm2Reactive Oxygen SpeciesRetinoblastoma Protein

Identifiers

PMID28835697
PMCPMC5569052
OpenAlexW2747079487

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.